Get the Stockscreener App
6.96
4.53%
-0.33
Pre-market:
7.00
0.04
+0.57%
Immunitybio Inc stock is traded at $6.96, with a volume of 10.83M.
It is down -4.53% in the last 24 hours and down -5.69% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.29
Open:
$7.25
24h Volume:
10.83M
Relative Volume:
0.39
Market Cap:
$7.19B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-17.86
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-14.07%
1M Performance:
-5.69%
6M Performance:
+169.77%
1Y Performance:
+164.64%
1-Day Range:
$6.91
$7.27
1-Week Range:
$6.91
$8.38
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
6.96 | 7.19B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio CEO Discusses Plans For Dunkirk Plant - Post Journal
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman - GlobeNewswire Inc.
FinancialContentImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class ActionContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
Caroline Campbell Filmed Anktiva Promo Videos While Insider Trading on FDA Rejection - hannahhowell.com
Is IBRX Priced for Perfection at Nearly 28x Forward Sales? - Yahoo! Finance Canada
What Makes ImmunityBio (IBRX) a New Buy Stock - Yahoo Finance
IBRX: What Anktiva's Bladder Data Says About 2026 Sales - Zacks Investment Research
IBRX Founder Backs Trump’s Psychedelic Push In ‘Transforming’ Health Policy — Flags New Anktiva Breast Cancer Risk Data - Stocktwits
IBRX stock rally not over yet? Chairman says Trump diplomacy led to ‘amazing results’ for cancer drug - MSN
ImmunityBio founder pushes back after FDA warning letter over Anktiva claims — says ad never aired at all - MSN
ImmunityBio rises on China nod to bladder cancer combo therapy - MSN
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio stock tumbles 25% on FDA warning. No, its drug can’t treat all cancers. - MSN
IBRX stock gains steam: Founder teases balance sheet ‘strengthening’ and global push as bears finally step back - MSN
ImmunityBio Stock Short Interest Rises to 37.06% - Quiver Quantitative
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - PR Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - NewMediaWire
IBRX stock in spotlight as FDA scrutiny prompts ImmunityBio to withdraw content, tighten oversight - MSN
Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio’s (IBRX) Commercial Strategy? - Yahoo Finance
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Stock Rattled As FDA Warning Triggers Class Actions - timothysykes.com
ImmunityBio (NASDAQ:IBRX) Market Moves and Biotech Sector Signals - Kalkine Media
ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.2%Time to Sell? - MarketBeat
IBRX Stock Slides As FDA Warning Letter Sparks Class Actions - StocksToTrade
IBRX Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia - Insider Monkey
IBRX DEADLINE: The Gross Law Firm Reminds ImmunityBio, Inc. - GlobeNewswire
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
Immunity Bio responds to FDA concerns over Anktiva marketing materials - MSN
ImmunityBio rally causes $492M paper losses for short sellers - MSN
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit- Hagens Berman - PR Newswire
ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline - The Globe and Mail
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):